Reza Jahan

Reza Jahan

Auto-generated profile, based on publicly available information

Reza Jahan

UCLA, Los Angeles, CA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2019 in JAMA
Verified
Journal Article
Open access
PDF file
RJReza Jahan
Reza Jahan
JSJeffrey L. Saver
Jeffrey L. Saver
LSLee H. Schwamm
Lee H. Schwamm
GFGregg C. Fonarow
Gregg C. Fonarow
LLLi Liang
Li Liang
ESEric E. Smith
Eric E. Smith
Quiz Ref ID Randomized clinical trials (RCTs) have demonstrated the benefit of endovascular-reperfusion therapy over medical therapy among patients with large vessel occlusion in acute ischemic stroke (AIS).1-6 Several studies suggest a strong time dependency of greater benefit with earlier treatment.7-10 Existing data regarding the relation of onset-to-treatment time and outcome, however, is limited in precision and representativeness. The pooled analysis of RCTs was of modest size (536 patients undergoing endovascular-reperfusion therapy in 5 trials),8 and RCT findings may not be directly generalizable to routine clinical practice. Observational studies similarly have been underpowered to delineate time effects with high precision.1,7,10,11 To address the need for analysis of a large, practice-based data set, the US nationwide Get With the Guidelines-Stroke (GWTG-Stroke) registry was analyzed to determine the association of time to treatment with outcomes from endovascular-reperfusion therapy.

1 May 2001 in Neurosurgery
Verified
Journal Article
Closed access
PDF file
RJReza Jahan
Reza Jahan
YMYuichi Murayama
Yuichi Murayama
YGY. Pierre Gobin
Y. Pierre Gobin
GDGary R. Duckwiler
Gary R. Duckwiler
HVHarry V. Vinters
Harry V. Vinters
FVFernando Viñuela
Fernando Viñuela
OBJECTIVE: To report our experience in treatment of arteriovenous malformations (AVMs) using a new liquid embolic agent, Onyx (Micro Therapeutics, Inc., Irvine, CA). METHODS: Between January 1998 and May 1999, 23 patients (8 men and 15 women) were treated. The patients' average age was 40 years, with seizure being the most common presenting symptom (39%). The average Spetzler-Martin grade on presentation was 3. The average AVM volume before embolization was 14.5 cm3. RESULTS: We observed an average 63% reduction in AVM volume after 129 arterial feeders were embolized. There were four adverse events. Two patients experienced ischemia because of inadvertent occlusion of an arterial feeder. One of these patients made a full recovery, but the other patient had a permanent deficit. Two other patients experienced transient neurological deficits that resolved within 1 week of embolization. Permanent morbidity was thus 4% (1 of 23 patients). There were no deaths. Twelve patients underwent subsequent radiosurgery, and 11 patients had surgery that resulted in complete resection of their AVMs. Histopathological examinations showed mild acute inflammation in specimens resected 1 day after embolization. Chronic inflammatory changes were observed in specimens resected more than 4 days after embolization. In two patients, angionecrosis of the embolized vessels was noted. No evidence of parenchymal hemorrhage was observed in these patients, and vessel wall integrity was maintained as well. CONCLUSION: Onyx is a new nonadhesive liquid embolic agent that has been used to treat 23 patients at our institution with good results. Its nonadhesive nature and ease of use make it a promising agent in the future treatment of AVMs.

15 July 2010 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
RJR. Jahan
R. Jahan
BACKGROUND AND PURPOSE: The extended time window and theoretic reduction in hemorrhage make mechanical strategies an attractive approach in the treatment of patients with ischemic stroke. My purpose was to evaluate the recanalization efficacy and safety of the Solitaire FR Revascularization Device in a swine vessel occlusion model. MATERIALS AND METHODS: For recanalization efficacy, radio-opaque clots were used in 6 ascending pharyngeal arteries of the swine. Safety was assessed in 8 renal arteries with 3 passes of the device. Four vessels were harvested at 30 days, and 4, at 90 days, with microscopic examination to assess vessel damage. RESULTS: On deployment, immediate flow was seen in 3/6 vessels; and on retrieval, TIMI-3 recanalization was seen in 6/6. Vasospasm, which resolved on follow-up angiography with no distal emboli or vessel damage, was noted. In the renal vessels, safety evaluation findings were unremarkable, with the exception of 2 vessels harvested from a kidney at 90 days. These 2 vessels appeared without damage on microscopy; however, angiography showed shrinkage of the entire kidney, which was attributed to damage and stenosis of the main renal artery at the site of the guide-catheter insertion, likely leading to a chronic low-flow state and resultant atrophy of the entire kidney. CONCLUSIONS: The Solitaire Device showed good recanalization efficacy with acceptable safety. The unique stent-like design allows immediate flow restoration, a distinct advantage of the device. On the basis of this study, the device has good potential as a tool in the treatment of patients with ischemic stroke.

1 December 2009 in Human Pathology
Verified
Journal Article
Closed access
RMRupal I Mehta
Rupal I Mehta
RMRashi I Mehta
Rashi I Mehta
MFMichael C Fishbein
Michael C Fishbein
OSOrestes E Solis
Orestes E Solis
RJReza Jahan
Reza Jahan
WYWilliam H Yong
William H Yong

1 July 2021 in Stroke
Verified
Journal Article
Open access
PDF file
OZOsama O. Zaidat
Osama O. Zaidat
David S. LiebeskindDavid S. Liebeskind
David S. Liebeskind
AJAshutosh P. Jadhav
Ashutosh P. Jadhav
SGSantiago Ortega Gutierrez
Santiago Ortega Gutierrez
Thanh N NguyenThanh N Nguyen
Thanh N Nguyen
NMNils H. Mueller-Kronast
Nils H. Mueller-Kronast
Background and Purpose: This study investigates clinical outcomes after mechanical thrombectomy in adult patients with baseline Alberta Stroke Program Early CT Score (ASPECTS) of 0 to 5. Methods: We included data from the STRATIS Registry (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke) from patients who underwent mechanical thrombectomy within 8 hours of symptom onset and had available ASPECTS data adjudicated by an independent core laboratory. Angiographic and clinical outcomes were collected, including successful reperfusion (modified Thrombolysis in Cerebral Infarction ≥2b), functional independence (modified Rankin Scale score 0–2), 90-day mortality, and symptomatic intracranial hemorrhage at 24 hours. Outcomes were stratified by ASPECTS scores and age. Results: Of the 984 patients enrolled, 763 had available ASPECTS data. Of these patients, 57 had ASPECTS of 0 to 5 with a median age of 63 years (interquartile range, 28–100), whereas 706 patients had ASPECTS of 6 to 10 with a median age of 70 years of age (interquartile range, 19–100). Ten patients had ASPECTS of 0 to 3 and 47 patients had ASPECTS of 4 to 5 at baseline. Successful reperfusion was achieved in 85.5% (47/55) in the ASPECTS of 0 to 5 group. Functional independence was achieved in 28.8% (15/52) in the ASPECTS of 0 to 5 versus 59.7% (388/650) in the 6 to 10 group ( P <0.001). Mortality rates were 30.8% (16/52) in the ASPECTS of 0 to 5 and 13.4% (87/650) in the 6 to 10 group ( P <0.001). sICH rates were 7.0% (4/57) in the ASPECTS of 0 to 5 and 0.9% (6/682) in the 6 to 10 group ( P 75 years with ASPECTS of 0 to 5 (0/12) achieved functional independence versus 44.8% (13/29) of those age ≤65 ( P =0.005). Conclusions: Patients 75 years of age. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02239640.

1 May 2008 in Stroke
Verified
Journal Article
Closed access
PDF file
RJReza Jahan
Reza Jahan
DSDaphne Stewart
Daphne Stewart
HVHarry V. Vinters
Harry V. Vinters
WYWilliam Yong
William Yong
FVFernando Vinuela
Fernando Vinuela
VMVictor J. Marder
Victor J. Marder
Background and Purpose— An animal model of selective middle cerebral artery (MCA) occlusion is needed for evaluation of intra-arterial (IA) delivery of thrombolytic agents. We describe a technique for MCA thrombo-occlusion in the rabbit with real-time angiographic documentation of occlusion and thrombolytic recanalization. Methods— After femoral artery cutdown, a microcatheter was advanced from the internal carotid artery to the MCA. MCA occlusion was achieved by IA thrombin and reperfusion by IA plasmin. Results— The terminal internal carotid artery was successfully catheterized in 12 of 13 animals. Stable (2-hour) MCA occlusion was induced and verified angiographically in all 12 animals; 2 animals also had distal internal carotid artery thrombus. Recanalization was achieved rapidly after IA plasmin in 3 of 3 animals. Conclusions— We describe a new animal model of selective MCA occlusion documented by real-time angiography and used to demonstrate recanalization with IA plasmin.